首页 > 最新文献
paperpass

Nature Reviews Neurology最新文献

英文 中文
Menopause and neurological disorders: a roadmap for research 更年期和神经系统疾病:研究路线图。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-08-10 DOI: 10.1038/s41582-026-01244-5
Riley Bove, Ruth Dobson
Menopause is under-recognized as a biological and sociocultural contributor to brain health, and scientific understanding of the impact that the menopausal transition has on the brain is minimal. This knowledge gap is particularly detrimental for women who live with neurological conditions. We lack sufficient data to understand the experience of women with established neurological conditions during perimenopause, the mechanisms associated with postmenopausal changes in disease course and how to improve management of neurological conditions in a sex-specific way. Furthermore, approximately two thirds of women experience cognitive concerns during the menopausal transition. Although earlier menopause is associated with a greater risk of cognitive decline, the influence of the menopausal transition on subsequent risk of neurological conditions remains unclear. In this Roadmap, we identify key areas in which research is limited and highlight historical and scientific challenges that have hindered progress in understanding brain health in the context of menopause. To address these challenges, we consider existing knowledge and propose priorities and future research directions to advance our understanding of the relationship between menopause and neurological health and disease. Menopause is under-recognized as a contributor to brain health, and we lack understanding of its interactions with neurological conditions. In this Roadmap, Bove and Dobson identify where research is limited and propose future research directions to further our understanding of the relationship between menopause and neurological health and disease.
更年期对大脑健康的生物学和社会文化影响尚未得到充分认识,对更年期过渡对大脑影响的科学理解也很少。这种知识差距对患有神经系统疾病的妇女尤其有害。我们缺乏足够的数据来了解围绝经期有神经系统疾病的妇女的经历,与绝经后疾病进程变化相关的机制,以及如何以性别特异性的方式改善神经系统疾病的管理。此外,大约三分之二的妇女在更年期过渡期间经历认知问题。虽然早期绝经与认知能力下降的风险较大有关,但绝经过渡对随后神经系统疾病风险的影响尚不清楚。在本路线图中,我们确定了研究有限的关键领域,并强调了阻碍了解更年期背景下大脑健康进展的历史和科学挑战。为了应对这些挑战,我们考虑了现有的知识,并提出了优先事项和未来的研究方向,以促进我们对更年期与神经系统健康和疾病之间关系的理解。
{"title":"Menopause and neurological disorders: a roadmap for research","authors":"Riley Bove, Ruth Dobson","doi":"10.1038/s41582-026-01244-5","DOIUrl":"10.1038/s41582-026-01244-5","url":null,"abstract":"Menopause is under-recognized as a biological and sociocultural contributor to brain health, and scientific understanding of the impact that the menopausal transition has on the brain is minimal. This knowledge gap is particularly detrimental for women who live with neurological conditions. We lack sufficient data to understand the experience of women with established neurological conditions during perimenopause, the mechanisms associated with postmenopausal changes in disease course and how to improve management of neurological conditions in a sex-specific way. Furthermore, approximately two thirds of women experience cognitive concerns during the menopausal transition. Although earlier menopause is associated with a greater risk of cognitive decline, the influence of the menopausal transition on subsequent risk of neurological conditions remains unclear. In this Roadmap, we identify key areas in which research is limited and highlight historical and scientific challenges that have hindered progress in understanding brain health in the context of menopause. To address these challenges, we consider existing knowledge and propose priorities and future research directions to advance our understanding of the relationship between menopause and neurological health and disease. Menopause is under-recognized as a contributor to brain health, and we lack understanding of its interactions with neurological conditions. In this Roadmap, Bove and Dobson identify where research is limited and propose future research directions to further our understanding of the relationship between menopause and neurological health and disease.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 9","pages":"581-601"},"PeriodicalIF":31.2,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148707204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumour and microenvironment targeting of glioblastoma with dual-acting CAR T cells 双作用CAR - T细胞靶向胶质母细胞瘤的肿瘤和微环境。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-08-05 DOI: 10.1038/s41582-026-01254-3
Lisa Kiani
A new study reports a CAR T cell therapy that concurrently targets the tumour and the pro-tumour microenvironment through a shared antigen. The new strategy could help to overcome key limitations of current therapies.
一项新的研究报道了一种通过共享抗原同时靶向肿瘤和促肿瘤微环境的CAR - T细胞疗法。这种新策略可能有助于克服当前治疗方法的关键局限性。
{"title":"Tumour and microenvironment targeting of glioblastoma with dual-acting CAR T cells","authors":"Lisa Kiani","doi":"10.1038/s41582-026-01254-3","DOIUrl":"10.1038/s41582-026-01254-3","url":null,"abstract":"A new study reports a CAR T cell therapy that concurrently targets the tumour and the pro-tumour microenvironment through a shared antigen. The new strategy could help to overcome key limitations of current therapies.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 9","pages":"544-544"},"PeriodicalIF":31.2,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148679504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Losing sleep over glia: new mechanisms for Alzheimer-related sleep disruption 神经胶质导致睡眠不足:阿尔茨海默病相关睡眠中断的新机制。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-08-04 DOI: 10.1038/s41582-026-01255-2
Brendan P. Lucey, Michael J. Howell
Sleep disruption in Alzheimer disease has long been viewed as a downstream consequence of amyloid and tau. Two new studies show that glia-mediated mechanisms involving microglia and astrocytic aquaporin 4, rather than amyloid plaque burden, disrupt sleep and are potential targets to prevent Alzheimer disease-related sleep loss.
长期以来,阿尔茨海默病的睡眠中断一直被视为淀粉样蛋白和tau蛋白的下游后果。两项新的研究表明,胶质介导的机制包括小胶质细胞和星形细胞水通道蛋白4,而不是淀粉样斑块负担,破坏睡眠,是预防阿尔茨海默病相关睡眠缺失的潜在目标。
{"title":"Losing sleep over glia: new mechanisms for Alzheimer-related sleep disruption","authors":"Brendan P. Lucey, Michael J. Howell","doi":"10.1038/s41582-026-01255-2","DOIUrl":"10.1038/s41582-026-01255-2","url":null,"abstract":"Sleep disruption in Alzheimer disease has long been viewed as a downstream consequence of amyloid and tau. Two new studies show that glia-mediated mechanisms involving microglia and astrocytic aquaporin 4, rather than amyloid plaque burden, disrupt sleep and are potential targets to prevent Alzheimer disease-related sleep loss.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 10","pages":"604-605"},"PeriodicalIF":31.2,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
White matter disorders at the intersection of transcription, RNA processing and translation 转录、RNA加工和翻译交叉处的白质紊乱。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-08-03 DOI: 10.1038/s41582-026-01248-1
Alexandra Chapleau, Felipe Villa Tobón, Geneviève Bernard
Hereditary white matter disorders, encompassing leukodystrophies and genetically determined leukoencephalopathies, are a heterogeneous group of conditions characterized by white matter signal abnormalities on neuroimaging. An increasing number of these disorders are now associated with defects in genes that encode proteins involved in transcription, RNA processing and translation. Pathogenic variants in these genes disrupt fundamental processes of the central dogma yet manifest primarily as neurological diseases, often presenting with diverse clinical and radiological features. Although many of these conditions have been recognized for over a decade, their underlying pathophysiological mechanisms and the selective vulnerability of the CNS and myelin remain incompletely understood. Here we provide a comprehensive overview of white matter disorders arising from defects in protein biosynthesis pathways. We summarize known disease-causing genes and their molecular consequences and associated clinical and radiological phenotypes, and highlight emerging mechanistic themes and therapeutic strategies across this expanding class of disorders. This Review provides a comprehensive overview of white matter disorders, encompassing leukodystrophies and genetically determined leukoencephalopathies, that arise from defects in protein biosynthesis pathways. The authors highlight the role of causal genes across transcription, RNA processing and translation and summarize the clinical and radiological features of these disorders, as well as emerging therapeutic strategies.
遗传性白质疾病,包括白质营养不良和遗传决定的白质脑病,是一组异质性的疾病,其特征是神经影像学上的白质信号异常。现在,越来越多的这些疾病与编码参与转录、RNA加工和翻译的蛋白质的基因缺陷有关。这些基因的致病变异破坏了中枢法则的基本过程,但主要表现为神经系统疾病,通常表现为不同的临床和放射学特征。尽管这些疾病中的许多已经被认识了十多年,但其潜在的病理生理机制以及中枢神经系统和髓磷脂的选择性易感性仍然不完全清楚。在这里,我们提供了一个全面的概述白质紊乱引起的蛋白质生物合成途径的缺陷。我们总结了已知的致病基因及其分子后果以及相关的临床和放射学表型,并强调了在这一不断扩大的疾病类别中出现的机制主题和治疗策略。
{"title":"White matter disorders at the intersection of transcription, RNA processing and translation","authors":"Alexandra Chapleau, Felipe Villa Tobón, Geneviève Bernard","doi":"10.1038/s41582-026-01248-1","DOIUrl":"10.1038/s41582-026-01248-1","url":null,"abstract":"Hereditary white matter disorders, encompassing leukodystrophies and genetically determined leukoencephalopathies, are a heterogeneous group of conditions characterized by white matter signal abnormalities on neuroimaging. An increasing number of these disorders are now associated with defects in genes that encode proteins involved in transcription, RNA processing and translation. Pathogenic variants in these genes disrupt fundamental processes of the central dogma yet manifest primarily as neurological diseases, often presenting with diverse clinical and radiological features. Although many of these conditions have been recognized for over a decade, their underlying pathophysiological mechanisms and the selective vulnerability of the CNS and myelin remain incompletely understood. Here we provide a comprehensive overview of white matter disorders arising from defects in protein biosynthesis pathways. We summarize known disease-causing genes and their molecular consequences and associated clinical and radiological phenotypes, and highlight emerging mechanistic themes and therapeutic strategies across this expanding class of disorders. This Review provides a comprehensive overview of white matter disorders, encompassing leukodystrophies and genetically determined leukoencephalopathies, that arise from defects in protein biosynthesis pathways. The authors highlight the role of causal genes across transcription, RNA processing and translation and summarize the clinical and radiological features of these disorders, as well as emerging therapeutic strategies.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 10","pages":"625-651"},"PeriodicalIF":31.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148670311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Towards a biologically informed description of multiple sclerosis disease course — a roadmap for transition 迈向多发性硬化症病程的生物学信息描述-过渡路线图。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-08-03 DOI: 10.1038/s41582-026-01249-0
Alan J. Thompson, Fred D. Lublin, Lindsay Rechtman, James Quinn, Maria Pia Amato, Bruce Bebo, Peter A. Calabresi, Julie Fiol, Marcia Finlayson, Annie Hawton, Tanja Kuhlmann, Ruth Ann Marrie, Marcello Moccia, Xavier Montalban, Michael Panzara, Kathy Smith, Maria Pia Sormani, Jon Strum, Barbara G. Vickrey, Timothy Coetzee, on behalf of the 2025 International Advisory Committee on Clinical Trials in Multiple Sclerosis
Contemporary management of multiple sclerosis is based on the clinical course descriptors of relapsing–remitting, secondary progressive and primary progressive. However, recognition is growing in the field that these clinical course descriptors do not capture the full disease spectrum of multiple sclerosis or reflect the underlying biological mechanisms of disease, and that biologically informed course descriptors are needed. In this Roadmap, participants in an International Advisory Committee on Clinical Trials in Multiple Sclerosis workshop discuss the problems with the existing course descriptors, highlight considerations for developing new course descriptors and propose a roadmap for transitioning towards a more dynamic, biologically informed description of the multiple sclerosis disease course. The current clinical course descriptors of multiple sclerosis do not capture the full disease spectrum or reflect the underlying biological mechanisms. In this Roadmap, the International Advisory Committee on Clinical Trials in Multiple Sclerosis proposes a roadmap for transitioning towards biologically informed descriptors of the multiple sclerosis disease course.
当代多发性硬化症的治疗是基于复发-缓解、继发性进展和原发性进展的临床病程描述。然而,该领域越来越多的人认识到,这些临床病程描述不能反映多发性硬化症的全部疾病谱系,也不能反映疾病的潜在生物学机制,因此需要有生物学信息的病程描述。在本路线图中,多发性硬化症临床试验国际咨询委员会研讨会的参与者讨论了现有病程描述的问题,强调了开发新病程描述的考虑因素,并提出了一个路线图,以过渡到一个更动态的,生物学上知情的多发性硬化症病程描述。
{"title":"Towards a biologically informed description of multiple sclerosis disease course — a roadmap for transition","authors":"Alan J. Thompson, Fred D. Lublin, Lindsay Rechtman, James Quinn, Maria Pia Amato, Bruce Bebo, Peter A. Calabresi, Julie Fiol, Marcia Finlayson, Annie Hawton, Tanja Kuhlmann, Ruth Ann Marrie, Marcello Moccia, Xavier Montalban, Michael Panzara, Kathy Smith, Maria Pia Sormani, Jon Strum, Barbara G. Vickrey, Timothy Coetzee, on behalf of the 2025 International Advisory Committee on Clinical Trials in Multiple Sclerosis","doi":"10.1038/s41582-026-01249-0","DOIUrl":"10.1038/s41582-026-01249-0","url":null,"abstract":"Contemporary management of multiple sclerosis is based on the clinical course descriptors of relapsing–remitting, secondary progressive and primary progressive. However, recognition is growing in the field that these clinical course descriptors do not capture the full disease spectrum of multiple sclerosis or reflect the underlying biological mechanisms of disease, and that biologically informed course descriptors are needed. In this Roadmap, participants in an International Advisory Committee on Clinical Trials in Multiple Sclerosis workshop discuss the problems with the existing course descriptors, highlight considerations for developing new course descriptors and propose a roadmap for transitioning towards a more dynamic, biologically informed description of the multiple sclerosis disease course. The current clinical course descriptors of multiple sclerosis do not capture the full disease spectrum or reflect the underlying biological mechanisms. In this Roadmap, the International Advisory Committee on Clinical Trials in Multiple Sclerosis proposes a roadmap for transitioning towards biologically informed descriptors of the multiple sclerosis disease course.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 10","pages":"652-660"},"PeriodicalIF":31.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148670277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to ‘Low-field MRI for equitable epilepsy diagnosis in resource-limited settings’ 回复“低场MRI在资源有限的环境中用于公平的癫痫诊断”。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-07-29 DOI: 10.1038/s41582-026-01253-4
Tavia E. Evans, Joshua Harper, Aram Salehi, Andrew G. Webb, James H. Cole, Ana Correa, Hieab H. H. Adams, Dave M. Cash, Derek K. Jones
{"title":"Reply to ‘Low-field MRI for equitable epilepsy diagnosis in resource-limited settings’","authors":"Tavia E. Evans, Joshua Harper, Aram Salehi, Andrew G. Webb, James H. Cole, Ana Correa, Hieab H. H. Adams, Dave M. Cash, Derek K. Jones","doi":"10.1038/s41582-026-01253-4","DOIUrl":"10.1038/s41582-026-01253-4","url":null,"abstract":"","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 10","pages":"662-662"},"PeriodicalIF":31.2,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low-field MRI for equitable epilepsy diagnosis in resource-limited settings 低场磁共振成像在资源有限的环境中公平的癫痫诊断。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-07-29 DOI: 10.1038/s41582-026-01252-5
Melody T. Asukile, Josemir W. Sander, John S. Duncan
{"title":"Low-field MRI for equitable epilepsy diagnosis in resource-limited settings","authors":"Melody T. Asukile, Josemir W. Sander, John S. Duncan","doi":"10.1038/s41582-026-01252-5","DOIUrl":"10.1038/s41582-026-01252-5","url":null,"abstract":"","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 10","pages":"661-661"},"PeriodicalIF":31.2,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Newborn screening is the missing step in spinal muscular atrophy care 新生儿筛查是脊髓性肌萎缩症护理中缺失的一步。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-07-28 DOI: 10.1038/s41582-026-01250-7
Jesy Nelson, Giles Lomax
Disease-modifying therapies for spinal muscular atrophy have transformed the disease prognosis, yet many children continue to face substantial disability owing to delayed diagnosis. Rapid implementation of newborn screening is imperative to offer life-changing interventions for affected families.
脊髓性肌萎缩症的疾病改善疗法已经改变了疾病的预后,但许多儿童由于诊断延迟而继续面临严重的残疾。迅速实施新生儿筛查对于为受影响家庭提供改变生活的干预措施至关重要。
{"title":"Newborn screening is the missing step in spinal muscular atrophy care","authors":"Jesy Nelson, Giles Lomax","doi":"10.1038/s41582-026-01250-7","DOIUrl":"10.1038/s41582-026-01250-7","url":null,"abstract":"Disease-modifying therapies for spinal muscular atrophy have transformed the disease prognosis, yet many children continue to face substantial disability owing to delayed diagnosis. Rapid implementation of newborn screening is imperative to offer life-changing interventions for affected families.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 9","pages":"535-537"},"PeriodicalIF":31.2,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148605480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Brain-first and body-first subtypes of Lewy body disease 路易体病的脑优先亚型和体优先亚型
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-07-16 DOI: 10.1038/s41582-026-01241-8
Per Borghammer, Nathalie Van Den Berge, Daniela Berg, Ryosuke Takahashi, Ronald B. Postuma, Jacob Horsager
People with Lewy body disease exhibit heterogeneous clinical symptoms, diverse patterns of neurodegeneration on imaging and variable Lewy body pathology at post-mortem. The brain-first versus body-first (BvB) model provides a unifying framework that may account for much of this variability. According to the BvB model, Lewy pathology originates either in autonomic nerves of the gut or other peripheral neurons (body first) or in the olfactory bulb with subsequent spread to the limbic system (brain first). Both subtypes are thought to begin largely outside the CNS, possibly triggered by exogenous factors such as infectious agents or toxins. The model is supported by several observations. First, some individuals develop autonomic dysfunction and sleep disorders years before diagnosis, whereas other individuals experience these symptoms only after diagnosis. Second, in people with prodromal sleep disorders, cardiac sympathetic denervation precedes nigrostriatal degeneration by approximately a decade, whereas in individuals without sleep disorders, these systems degenerate in the opposite sequence. Third, post-mortem studies often reveal bottom-up or top-down gradients of Lewy pathology, consistent with body-first versus olfactory-first origins. This Review provides a critical appraisal of the BvB model, highlighting supporting evidence and current limitations. The article also considers implications for diagnostics, therapy and prevention, and outlines key avenues for future research. The brain-first versus body-first model proposes that Lewy body disease can originate from different pathogenic routes, accounting for heterogeneity in symptoms, neurodegeneration patterns and post-mortem pathology. Here, Borghammer et al. evaluate the evidence for this model, outline its implications for diagnosis, therapy and prevention, and identify priorities for future research.
路易体病患者表现出不同的临床症状、影像学上不同的神经退行性变模式和死后不同的路易体病理。脑优先vs身体优先(BvB)模型提供了一个统一的框架,可以解释这种差异的大部分。根据BvB模型,Lewy病理起源于肠道或其他周围神经元的自主神经(身体优先)或嗅球,随后扩散到边缘系统(大脑优先)。这两种亚型被认为主要起源于中枢神经系统外,可能是由外源性因素如感染性病原体或毒素引发的。该模型得到了若干观测结果的支持。首先,一些人在诊断前几年就出现自主神经功能障碍和睡眠障碍,而另一些人在诊断后才出现这些症状。其次,在患有前驱睡眠障碍的人群中,心脏交感神经去支配先于黑质纹状体退化大约十年,而在没有睡眠障碍的个体中,这些系统的退化顺序相反。第三,死后研究经常揭示路易氏病理自下而上或自上而下的梯度,与身体优先与嗅觉优先的起源一致。本综述对BvB模型进行了批判性评价,强调了支持证据和当前的局限性。文章还考虑了对诊断、治疗和预防的影响,并概述了未来研究的关键途径。脑优先与身体优先模型提出,路易体病可能起源于不同的致病途径,解释了症状、神经变性模式和死后病理的异质性。在这里,博格哈默等人评估了该模型的证据,概述了其对诊断、治疗和预防的影响,并确定了未来研究的重点。
{"title":"Brain-first and body-first subtypes of Lewy body disease","authors":"Per Borghammer, Nathalie Van Den Berge, Daniela Berg, Ryosuke Takahashi, Ronald B. Postuma, Jacob Horsager","doi":"10.1038/s41582-026-01241-8","DOIUrl":"10.1038/s41582-026-01241-8","url":null,"abstract":"People with Lewy body disease exhibit heterogeneous clinical symptoms, diverse patterns of neurodegeneration on imaging and variable Lewy body pathology at post-mortem. The brain-first versus body-first (BvB) model provides a unifying framework that may account for much of this variability. According to the BvB model, Lewy pathology originates either in autonomic nerves of the gut or other peripheral neurons (body first) or in the olfactory bulb with subsequent spread to the limbic system (brain first). Both subtypes are thought to begin largely outside the CNS, possibly triggered by exogenous factors such as infectious agents or toxins. The model is supported by several observations. First, some individuals develop autonomic dysfunction and sleep disorders years before diagnosis, whereas other individuals experience these symptoms only after diagnosis. Second, in people with prodromal sleep disorders, cardiac sympathetic denervation precedes nigrostriatal degeneration by approximately a decade, whereas in individuals without sleep disorders, these systems degenerate in the opposite sequence. Third, post-mortem studies often reveal bottom-up or top-down gradients of Lewy pathology, consistent with body-first versus olfactory-first origins. This Review provides a critical appraisal of the BvB model, highlighting supporting evidence and current limitations. The article also considers implications for diagnostics, therapy and prevention, and outlines key avenues for future research. The brain-first versus body-first model proposes that Lewy body disease can originate from different pathogenic routes, accounting for heterogeneity in symptoms, neurodegeneration patterns and post-mortem pathology. Here, Borghammer et al. evaluate the evidence for this model, outline its implications for diagnosis, therapy and prevention, and identify priorities for future research.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 9","pages":"564-580"},"PeriodicalIF":31.2,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148459631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurological symptoms in survivors of Ebola virus disease 埃博拉病毒病幸存者的神经系统症状。
IF 31.2 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-07-14 DOI: 10.1038/s41582-026-01247-2
Lisa Kiani
Ebola virus disease is associated with a broad range of long-term neurological sequalae, a new study reports.
一项新的研究报告称,埃博拉病毒病与广泛的长期神经后遗症有关。
{"title":"Neurological symptoms in survivors of Ebola virus disease","authors":"Lisa Kiani","doi":"10.1038/s41582-026-01247-2","DOIUrl":"10.1038/s41582-026-01247-2","url":null,"abstract":"Ebola virus disease is associated with a broad range of long-term neurological sequalae, a new study reports.","PeriodicalId":19085,"journal":{"name":"Nature Reviews Neurology","volume":"22 8","pages":"481-481"},"PeriodicalIF":31.2,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41582-026-01247-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148441130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Nature Reviews Neurology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
mjeditor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1